bs-0784R [Primary Antibody]
IFNB1 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: IFNB1

Immunogen Range: 101-184/184


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 24481

Swiss Prot: P01575

Source: KLH conjugated synthetic peptide derived from mouse IFNB1

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

The mammalian type I Inteferons (IFN1) are produced in response to viral infection and other inducers. They are divided into alpha and beta subtypes leukocytes and fibroblasts reactivity. The human IFN alphas are encoded by a family of at least 15 different genes, while IFN beta is the unique member of its subtype. There is approximately 50% amino acid homology between the alpha and beta subtypes. Both IFN subtypes are pleiotropic cytokines and have a similar range of biological activities. Differences between alpha subtypes, and between IFN alpha and betas, are in potency and cell type specific activities. In particular, IFN beta elicits a markedly higher antiproliferation response in some cell types such as, embryonal carcinoma, melanoma and melanocytes than do IFN alphas. Higher potency of IFN beta in treatment of multiple sclerosis and certain cancers has been observed. Type I IFNs signal through binding to a common cell surface receptor. Two chains of the receptor, IFNAR1 and IFNAR2, have been identified. Both chains are necessary for function and in the absence of either there is neither high affinity binding nor biological activity. The intracellular portions of the receptor subunits are bound by tyrosine kinases, Jak1 and Tyk2, members of the Janus kinase family. Upon ligand binding these kinases are activated and phosphorylate members of the STAT family of transcription factors, as well as IFNAR1 and 2.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 20


Cross Reactive Species: Human
Mouse

Predicted Cross Reactive Species: Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Liang Y et al. Astragalus Membranaceus Treatment Protects Raw264. 7 Cells from Influenza Virus by Regulating G1 Phase and the TLR3-Mediated Signaling Pathway. Evid Based Complement Alternat Med. 2019 Dec 31;2019:2971604. Read more>>
  • Pengfei Cheng. et al. A3 adenosine receptor agonist IB-MECA reverses chronic cerebral ischemia-induced inhibitory avoidance memory deficit. Eur J Pharmacol. 2022 Apr;921:174874Read more>>
  • Weihong Guo. et al. Improved immunotherapy for gastric cancer by nanocomposites with capability of triggering Dual-Damage of Nuclear/Mitochondrial DNA and cGAS/STING-Mediated innate immunity. CHEM ENG J. 2022 Sep;443:136428Read more>>
  • Yuxi Liang. et al. The crude extract from the flowers of Trollius chinensis Bunge exerts anti-influenza virus effects through modulation of the TLR3 signaling pathway. J ETHNOPHARMACOL. 2023 Jan;300:115743Read more>>
  • ingchen Zhang. et al. Precise RNA Editing: Cascade Self-Uncloaking Dual-Prodrug Nanoassemblies Based on CRISPR/Cas13a for Pleiotropic Immunotherapy of PD-L1-Resistant Colorectal Cancer. ADV FUNCT MATER. 2023 Sep;:230563Read more>>
VALIDATION IMAGES

Lane 1: Mouse RAW264.7 cell lysates; Lane 2: Human THP-1 cell lysates probed with IFN-beta Polyclonal Antibody, Unconjugated (bs-0784R) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.